Our Services

Trials360 specializes in providing a wide variety of services for both preclinical and clinical trials. Our services cover every stage of the clinical research process, including study startup, feasibility assessments and site selection, project management and medical monitoring. What distinguishes us is our highly qualified and skilled team, composed of professionals from various research backgrounds that add a wealth of experience to each project. You're not just getting a service when you work with Trials360; you're getting a collaborative ally committed to promoting research and driving innovation ahead.

Clinical Site Selection

Biostatistics

Quality Assurance

Study Start-Up

Regulatory Affairs

Data Management

Clinical Site Monitoring

Patient Recruitment

Pharmacovigilance 

Medical Writing

Therapeutic Coverage

Trials360 is committed to pushing the boundaries of medical sciences. Our dedicated team has unparalleled experience in conducting clinical trials in numerous therapeutic areas. Our customized solutions are designed to meet the specific needs of each therapeutic domain. Trials360 is in sync with the global demand in the therapeutic domains. We are dedicated to advancing medical science and improving patient outcomes across these critical fields of study:

Oncology
Infectious diseases & Vaccines
Cardiovascular diseases
Pre-Clinical Services
Immunology
Dermatology
Neurology
Endocrinology
Scroll to Top

Oncology

Pakistan is a developing country with a population of over 245 million ranked fifth in the world. The incidence of cancer is increasing in Pakistan with reported cases of 185 748 in 2022. Cancer is a leading cause of death worldwide. According to Globocan 2022, the most common cancer in women is breast cancer (31.3%), while in males it is oral cavity cancer (12.3%). The highest mortality in Pakistan, secondary to cancer, is also because of the breast (13.1%) and oral cavity (8.6%).  

At Trials360, we specialize in oncology clinical research, providing comprehensive and innovative solutions to advance cancer therapies. Our dedicated team of experts collaborates with potential sites to design and execute complex clinical trials, ensuring the highest standards of quality and efficiency. We leverage cutting-edge technology and a patient-centric approach to accelerate the development of next-generation cancer treatments. Trials360 services are tailored to meet the unique needs of each project, driving breakthroughs in oncology and bringing hope to patients worldwide.

Infectious diseases & Vaccines

According to the WHO, Pakistan is facing a double burden of disease, with endemic hepatitis B and C affecting 7.6% of the population, the 5th highest tuberculosis burden in the world. Drug-resistant tuberculosis is estimated at 4.3%, and the country also serves as a focal geographical area for malaria endemicity. The overall HIV prevalence is 21.0%. Additionally, dengue and polio remain prevalent WHO Health Statistics.

At Trials360, we provide research services to address the high prevalence of infectious diseases in Pakistan. We are dedicated to advancing the understanding and treatment of these diseases by offering comprehensive services that span from pre-clinical to clinical trials. Our team of experienced veterinarians and scientists utilizes in-depth knowledge of pathogens to develop and validate models that accurately mimic human infections. By partnering with us, clients gain access to a robust platform for testing the efficacy and safety of novel vaccines, ensuring a streamlined path from the lab to the patient.

Cardiovascular Diseases

Cardiovascular diseases remain a leading health concern in Pakistan, with approximately 18.9% of the population self-reporting CVD. The age-standardized incidence of CVD in Pakistan is 918.18 per 100,000 people, and the age-standardized death rate is 357.88 per 100,000. Among adults, 40.1% have hypertension, 5.8% have diabetes, and 7% are affected by ischemic heart disease. Cardiovascular diseases account for a significant portion of total deaths in Pakistan, with heart disease being a major contributor. The burden of CVD in Pakistan is particularly high, affecting a substantial portion of the population with conditions such as hypertension, diabetes, and ischemic heart disease. (https://doi.org/10.26719/emhj.22.083)

Trials360 is dedicated to advancing cardiovascular research through innovative clinical and pre-clinical trials with the support of CVD specialists. By partnering with healthcare providers and leveraging the latest scientific advancements, we aim to develop effective treatments and preventive strategies that can significantly reduce the incidence and impact of cardiovascular diseases. Together, we are committed to improving heart health and the quality of life for millions.

Pre-Clinical Services

Our comprehensive services include Proof of Concept studies, Model Preparation, Safety and Efficacy studies, Toxicology studies, and Dose Optimization. These offerings are designed to support the development and testing of innovative treatments, ensuring the highest standards of research and reliability.

At Trials360, we have developed an Acute Lung Injury (ALI) model in rats, which closely mimics the inflammatory response observed in the human respiratory system. This model provides a valuable platform for studying the mechanisms of respiratory inflammation and testing potential anti-inflammatory therapeutic agents. Our ALI rat model is instrumental in evaluating the efficacy of new drugs aimed at reducing inflammation and improving lung function. Additionally, our rat stroke model offers critical insights into the mechanisms of stroke and the efficacy of potential treatments, driving advancements in neuroprotective therapies and stroke recovery.

At Trials360, we excel in creating customized disease models across a variety of species, tailored to your specific drug, device, or treatment needs. Our expertise ensures precise simulation of human disease conditions, enabling reliable translational research and innovative therapeutic testing. We offer flexible experimental designs and rapid model development, helping to accelerate your research while maintaining high fidelity and impact.

Partner with us to explore the latest solutions using animal models, supported by a dedicated team committed to delivering reliable data.

Immunology

Immunological disorders represent a significant area of focus for scientists due to their complex nature and the critical need for innovative treatments. The chronic and debilitating nature of these diseases, which can lead to high medical costs and reduced quality of life, burdens patients and also affects their families and communities.

These disorders, which include autoimmune diseases, immunodeficiencies, and hypersensitivity reactions, pose unique challenges in clinical research. Trials360, specializing in immunology, leverages its extensive expertise to effectively design and execute clinical trials that address these challenges. By integrating advanced methodologies and comprehensive therapeutic knowledge, Trials360 can accelerate the development of new therapies, ensuring rigorous safety and efficacy standards are met. This collaborative approach advances scientific understanding and brings hope to patients suffering from these debilitating conditions.

At Trials360, we provide a broad range of basic, preclinical, and clinical research in autoimmune diseases to enhance understanding of the causes of these diseases, the genetic factors that make people susceptible to them, and the regulatory mechanisms that control the production of self-destructive antibodies. Trials360 supports research in developing a greater understanding of the fundamental immunologic principles underlying disease onset and progression, developing improved animal models of disease, improving diagnostic tools, and identifying and evaluating more effective immune-based treatment and prevention strategies.

Dermatology

In 2023, dermatological diseases in Pakistan showed significant prevalence. Scabies was the most reported skin condition, affecting about 45.55% of patients. Eczema followed, accounting for 19.6% of cases, while dermatitis represented 10.3% of the reported conditions. Other notable conditions included tinea capitis (5.7%), tinea corporis (2.9%), impetigo (2.7%), and folliculitis (2.6%). (https://doi.org/10.3390/medicina59111905).

Dermatological diseases encompass a wide range of conditions, posing significant health challenges globally. At Trials360, we are dedicated to advancing dermatological research and developing the latest solutions. Our team collaborates with leading dermatologists and healthcare professionals to conduct clinical trials that ensure the safety and efficacy of new dermatological products. We aim to improve patient health and enhance quality of life by providing effective solutions.

Neurology

Neurological diseases are a growing concern in Pakistan. Chronic non-infectious neurological disorders affect approximately 4% to 5% of the population in lower-income countries like Pakistan. The most prevalent neurological conditions include stroke, epilepsy, migraine, dementia, and Parkinson’s disease. During the COVID-19 lockdown, 39.9% of people in Pakistan experienced depression, and 57.7% suffered from anxiety, highlighting the significant mental health burden among neurological patients. (DOI:10.33545/2664908X.2023.v5.i1a.19) 

At Trials360, we specialize in advancing the understanding and treatment of complex neurological conditions through cutting-edge research and in vivo assessment. Our team of experts utilizes state-of-the-art animal models and translational tools to accurately replicate human neurological conditions, ensuring the highest relevance and reliability in our preclinical studies. We are committed to providing unparalleled expertise and accelerating the development of effective therapies for neurological diseases, ultimately aiming to transform patient outcomes and improve lives.

Endocrinology

In 2023, Pakistan continues to face significant challenges related to endocrinology diseases, particularly diabetes and thyroid disorders. The prevalence of diabetes has dramatically increased, affecting approximately 33 million adults. Additionally, non-communicable diseases (NCDs) such as cardiovascular diseases, cancers, and chronic respiratory diseases—many of which have endocrine components—account for 58% of all deaths in Pakistan. (https://doi.org/10.1136/ bmjopen-2023-079513).

Thyroid disorders are also a significant health concern, with both hypothyroidism and hyperthyroidism affecting a notable portion of the population. The prevalence of hypothyroidism is around 4.1%, while hyperthyroidism affects approximately 5.1% of the population. Subclinical forms of these disorders are common as well, with subclinical hypothyroidism at 5.4% and subclinical hyperthyroidism at 5.8%. (http://dx.doi.org/10.19045/bspab.2021.100071).

Endocrinology diseases, which primarily impact the intricate network of hormones and glands, present complex challenges in medical research and treatment.  At Trials360, we are at the forefront of advancing endocrinology research through comprehensive clinical trials. Our expertise covers a wide range of endocrine disorders, including diabetes, thyroid diseases, adrenal disorders, and metabolic syndromes. We ensure precise data collection and analysis, paving the way for the development of novel solutions. Our commitment to excellence and collaboration with leading healthcare providers enables us to accelerate the discovery of treatments that can significantly improve the quality of life for those affected by endocrine disorders.